Centivax Raises $37M to Advance Universal Flu Vaccine Into Clinical Trials
Most companies treat the flu like a yearly inconvenience. Centivax is treating it like a long-standing problem that finally ran into the wrong kind of engineer. South San Francisco just watched Centivax pull in $37M in an oversubscribed round, led by Structure Fund with Oliver Mulherin and Sam Altman in the mix, alongside Meiji Seika Pharma, Sigmas Group, Kendall Capital Partners, and a quiet flex from Patrick Collison and John Collison. Not a tourist list. This is a table where capital shows up because it sees something most people are still squinting at.
Credit where it is due. Congratulations to Jacob Glanville and Nicholas Bayless, alongside Sawsan Youssef and Stephanie Wisner, for building something that does not just talk about “better vaccines” like it is a TED Talk slide. Centivax is in the clinic with Centi Flu 01, already dosing humans as of February 2026, with nearly 180 participants enrolled in a Phase 1 that stretches toward 300. That is not theory. That is skin in the game, needles in arms, data on the clock.
The play here is not seasonal guessing games. Their epitope focusing approach pushes the immune system toward conserved regions of the virus, the parts that do not like to change even when everything else is mutating like it is trying to dodge rent. Translation for the non-lab crowd. Instead of chasing flu strains every year, Centivax is aiming at the flu’s pressure points. One shot that remembers what the virus tries to forget.
Now zoom out. Roughly 600 million flu shots a year, billions in market gravity, and effectiveness that can swing like a loose door in a storm. Centivax walks in and says maybe we stop playing defense annually and start building something that holds across seasons and surprises. That is not a small claim. That is the kind of claim that either folds fast or rewires expectations.
This $37M is not just fuel for Phase 2 in 2027. It is insurance against momentum loss. It is capital staged to move from Phase 1 straight through the next gate without the usual pause where science waits on spreadsheets. At the same time, they are pushing 4 more programs toward readiness, from oncology to malaria to a universal antivenom and an Alzheimer’s preventative concept. Ambitious, yes. But the architecture is consistent. Find what does not change, and build there.
A quieter layer sits underneath all of this. Meiji Seika Pharma is not just a logo on a slide. It signals distribution, manufacturing gravity, and access to a market that already understands flu at scale. Pair that with a planned cell free manufacturing process entering GMP in 2026, and the picture sharpens. This is a company thinking about production before the applause shows up.
The takeaway is not hype. It is discipline. Raise ahead of inflection points. Design science that compounds across programs. Bring in investors who understand both molecules and markets. Centivax is not asking for attention. It is building a case, one dataset at a time, that the flu might finally meet something it cannot easily outrun.
